<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00534001</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000565103</org_study_id>
    <secondary_id>I 57805</secondary_id>
    <nct_id>NCT00534001</nct_id>
  </id_info>
  <brief_title>Bupropion in Helping Adults Stop Smoking</brief_title>
  <official_title>A Phase II Study of the Effects of Extended Pre-Cessation Bupropion for Smoking Cessation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Bupropion may help people stop smoking by decreasing the symptoms of nicotine
      withdrawal. Giving bupropion over a longer period of time may be effective in helping people
      stop smoking.

      PURPOSE: This randomized phase II trial is studying how well bupropion works in helping
      adults stop smoking.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the feasibility of conducting a full-scale clinical trial to evaluate whether
           extending the duration of pre-cessation bupropion hydrochloride enhances smoking
           cessation, as measured by 3-month prolonged abstinence rates, in adult smokers.

      Secondary

        -  Assess baseline smoking and mood characteristics (nicotine dependence, smoking history,
           anxiety, and depression).

        -  Assess measures to address the hypothesized extinction mechanism (subjective effects of
           smoking, collection of cigarette butts for an assessment of nicotine and tar exposure,
           craving for smoking, and expectations for the consequences of smoking).

        -  Assess changes in affective state as measured by Withdrawal Symptoms Checklist and by
           Positive and Negative Affect Schedule (PANAS) questionnaire.

        -  Assess side effects, pill counts, and changes in daily smoking rate.

        -  Assess mental health, personality traits, interpersonal skills, demand simulation,
           impulsivity, motivation, and perceived stress using validated measures.

      OUTLINE: Participants are stratified according to gender. Participants are randomized to 1 of
      2 pre-cessation intervention arms.

        -  Arm I (1-week run-in): Participants receive an oral placebo once or twice daily in weeks
           1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants
           also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.

        -  Arm II (4-week run-in): Participants receive oral bupropion hydrochloride once or twice
           daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling
           sessions once in weeks 1, 2, and 4.

      In both arms, participants are asked to quit smoking (target quit date) in week 5. All
      participants then receive oral bupropion hydrochloride once or twice daily in weeks 5-11 and
      undergo 90-minute behavioral group counseling sessions once in weeks 5, 7, and 9.

      Participants complete questionnaires to collect information on tobacco use history, health
      habits, depression, anxiety scales/symptoms, and sociodemographics at baseline. Participants
      also complete a series of validated questionnaires about smoking patterns, smoking
      satisfaction, mental health, personality traits, interpersonal skills, demand simulation,
      impulsivity, motivation, and perceived stress at baseline and then periodically during study.
      Participants undergo saliva sample collection at baseline and then periodically during study.
      Samples are analyzed for the presence of cotinine. Buccal cells are also collected at
      baseline for subsequent DNA analyses. Cigarette butts from the first cigarette of the day,
      including the quit day, are collected during group counseling sessions in weeks 1, 2, 4, and
      5 and are assessed for a marker that indicates the amount of nicotine and tar consumed.

      After finishing study treatment, participants are followed at 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2015</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Prequit Change in Cigarettes Per Day</measure>
    <time_frame>3-Week PreQuit Drug Manipulation Phase</time_frame>
    <description>Prequit Change in Cigarettes Per Day</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abstinence</measure>
    <time_frame>4 weeks</time_frame>
    <description>Bioverified 4-week continuous abstinence</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">95</enrollment>
  <condition>Bladder Cancer</condition>
  <condition>Cervical Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Liver Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <condition>Tobacco Use Disorder</condition>
  <arm_group>
    <arm_group_label>Arm I (1-week run-in)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (4-week run-in)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bupropion hydrochloride</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (1-week run-in)</arm_group_label>
    <arm_group_label>Arm II (4-week run-in)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Given orally</description>
    <arm_group_label>Arm I (1-week run-in)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Currently smokes â‰¥ 15 cigarettes per day for at least 1 year

          -  Motivated to quit smoking within the next 3 months

        PATIENT CHARACTERISTICS:

          -  Willing to attend clinic visits

          -  Willing to refrain from nicotine replacement therapy (NRT) use during study
             participation

          -  Able to speak and read English fluently

          -  Has a home telephone and plans to reside in Western New York for the next year

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Not planning a pregnancy

          -  Fertile patients must use effective contraception during and for 3 months after study
             participation

          -  No history of chronic renal or hepatic disease

          -  No history of head trauma or seizure

          -  No history of a seizure disorder, brain tumor, or CNS tumor

          -  No history of or currently diagnosed bulimia or anorexia nervosa

          -  No history of psychotic disorder

          -  No diabetes requiring oral hypoglycemics or insulin

          -  No excessive use of alcohol or alcoholism

          -  No current addiction to opiates, cocaine, or stimulants

          -  No poorly controlled hypertension (i.e., systolic blood pressure [BP] &gt; 170 mm Hg
             and/or diastolic BP &gt; 110 mm Hg)

          -  No allergy to bupropion hydrochloride

          -  No other surgical or medical condition that may significantly alter absorption,
             distribution, metabolism, or excretion of bupropion hydrochloride

          -  No history of noncompliance to medical regimens

          -  No other clinical contraindication

          -  No major depressive disorder

        PRIOR CONCURRENT THERAPY:

          -  At least 14 days since prior and no concurrent monoamine oxidase inhibitor

          -  No recent discontinuation of a benzodiazepine

          -  No concurrent Hypericum perforatum (St. John's wort)

          -  No other concurrent drugs containing bupropion hydrochloride (e.g., Wellbutrin or
             Zyban)

          -  No concurrent antipsychotics, antidepressants, theophylline, systemic steroids,
             over-the-counter stimulants or anorectics, or levodopa

          -  No concurrent active treatment for cancer (e.g., chemotherapy or radiotherapy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Mahoney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 20, 2007</study_first_submitted>
  <study_first_submitted_qc>September 20, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 24, 2007</study_first_posted>
  <results_first_submitted>February 20, 2017</results_first_submitted>
  <results_first_submitted_qc>April 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 30, 2017</results_first_posted>
  <last_update_submitted>April 24, 2017</last_update_submitted>
  <last_update_submitted_qc>April 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bladder cancer</keyword>
  <keyword>cervical cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>adult primary liver cancer</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>small cell lung cancer</keyword>
  <keyword>pancreatic cancer</keyword>
  <keyword>hypopharyngeal cancer</keyword>
  <keyword>laryngeal cancer</keyword>
  <keyword>lip and oral cavity cancer</keyword>
  <keyword>nasopharyngeal cancer</keyword>
  <keyword>oropharyngeal cancer</keyword>
  <keyword>paranasal sinus and nasal cavity cancer</keyword>
  <keyword>adult acute myeloid leukemia</keyword>
  <keyword>tobacco use disorder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Tobacco Use Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>1-week Run In (Standard)</title>
        </group>
        <group group_id="P2">
          <title>4-week Run-in (Extended)</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="48"/>
                <participants group_id="P2" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="43"/>
                <participants group_id="P2" count="43"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I (1-week run-in)</title>
          <description>Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="B2">
          <title>Arm II (4-week run-in)</title>
          <description>Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="48"/>
            <count group_id="B2" value="47"/>
            <count group_id="B3" value="95"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.7" spread="9.3"/>
                    <measurement group_id="B2" value="45.8" spread="10.1"/>
                    <measurement group_id="B3" value="46" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Racial/Ethnic Minority</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White/Not Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cigarettes Smoked Per Day (CPD)</title>
          <units>CPD</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.0" spread="6.0"/>
                    <measurement group_id="B2" value="23.4" spread="7.9"/>
                    <measurement group_id="B3" value="23" spread="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Prequit Change in Cigarettes Per Day</title>
        <description>Prequit Change in Cigarettes Per Day</description>
        <time_frame>3-Week PreQuit Drug Manipulation Phase</time_frame>
        <population>Excludes participants with missing data (2 in Arm 1, 3 in Arm 2)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (1-week run-in)</title>
            <description>Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (4-week run-in)</title>
            <description>Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Prequit Change in Cigarettes Per Day</title>
          <description>Prequit Change in Cigarettes Per Day</description>
          <population>Excludes participants with missing data (2 in Arm 1, 3 in Arm 2)</population>
          <units>Cigarettes Per Day</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="46"/>
                <count group_id="O2" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.6" spread="0.5"/>
                    <measurement group_id="O2" value="-3.9" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Abstinence</title>
        <description>Bioverified 4-week continuous abstinence</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Arm I (1-week run-in)</title>
            <description>Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally
placebo: Given orally</description>
          </group>
          <group group_id="O2">
            <title>Arm II (4-week run-in)</title>
            <description>Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally</description>
          </group>
        </group_list>
        <measure>
          <title>Abstinence</title>
          <description>Bioverified 4-week continuous abstinence</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <desc>Only participant-volunteered side effects were noted.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm I (1-week run-in)</title>
          <description>Participants receive an oral placebo once or twice daily in weeks 1-3 followed by oral bupropion hydrochloride once or twice daily in week 4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally
placebo: Given orally</description>
        </group>
        <group group_id="E2">
          <title>Arm II (4-week run-in)</title>
          <description>Participants receive oral bupropion hydrochloride once or twice daily in weeks 1-4. Participants also undergo 90-minute behavioral group counseling sessions once in weeks 1, 2, and 4.
bupropion hydrochloride: Given orally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="48"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Any Non-Serious Adverse Event</sub_title>
                <description>Adverse events (not including serious) only tracked for clinical monitoring; all participants noted at least one adverse event during the 8-week period of monitoring.</description>
                <counts group_id="E1" events="48" subjects_affected="48" subjects_at_risk="48"/>
                <counts group_id="E2" events="47" subjects_affected="47" subjects_at_risk="47"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Martin Mahoney</name_or_title>
      <organization>Roswell Park Cancer Institute</organization>
      <phone>716-845-2300</phone>
      <email>martin.mahoney@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

